Sagent’s injectable antibiotics enter market
SCHAUMBURG, Ill. Generic drug maker Sagent Pharmaceuticals has launched two injectable antibiotics, the company said Tuesday.
Sagent announced the launch of ampicillin and ampicillin with sulbactam. Ampicillin had sales of around $42 million during the 12-month period ended in June, while ampicillin with sulbactam had sales of around $40 million during the same period, according to IMS Health.
“The launch of these products increases Sagent’s anti-infectives portfolio to 11 injectable products in a variety of sizes, concentrations and packaging configurations,” Sagent CEO and board chairman Jeffrey Yordon said.
FDA approves Par and Tris Pharma’s generic Tussionex
WOODCLIFF LAKE, N.J. The Food and Drug Administration has approved a generic treatment for cough and upper respiratory symptoms resulting from colds and allergies made by Par Pharmaceutical and Tris Pharma, Par said Tuesday.
The FDA approved hydrocodone polistirex and chlorpheniramine polistirex extended-release oral suspension. The drug is a generic version of UCB’s Tussionex, which has annual sales of around $226 million, according to IMS Health.
“The introduction of this first-to-market generic product will improve patient access to a much-needed therapy,” Par EVP and president Paul Campanelli said. “Our partner, Tris Pharma, has once again leveraged its innovative drug-delivery platform to bring this important product market.”
HGS, Novartis halt further development of Zalbin
ROCKVILLE, Md. Human Genome Sciences and Novartis have decided not to further develop an investigative biologic treatment for hepatitis C following the Food and Drug Administration’s decision to decline its approval, HGS said Tuesday.
HGS said it received a complete response letter from the FDA concerning the drug Zalbin (albinterferon alfa-2b). The FDA delivers a complete response letter to indicate that it has finished reviewing an application, but questions remain that preclude final approval.
HGS did not specify what the issues with the application were, but said it had expected to receive the letter.